★ Analysts see FY2026 revenue reaching $198M — -16.2% growth in a single year.
What Moves the Stock
01Vafseo commercial performance updates in Japan - prescription trends, market share gains against competitors like Evrenzo (roxadustat) and traditional ESAs
02Regulatory developments for vadadustat in potential new markets or indications beyond Japan approval
03Partnership announcements or licensing deals that provide non-dilutive capital and validate the HIF-PHI platform
04Cash runway updates and financing activities - equity raises, debt restructuring, or strategic alternatives given negative cash flow
05Clinical data readouts or safety updates for vadadustat, particularly any differentiation versus competing HIF-PHIs
06Collaboration revenue from Mitsubishi Tanabe Pharma for Vafseo (vadadustat) in Japan - milestone payments and royalties
07Historical Auryxia product revenue (divested rights to Akebia's US commercial operations in recent restructuring)
08Potential future licensing deals or milestone payments from vadadustat development programs
speculation - Akebia attracts high-risk biotech investors and event-driven traders betting on binary outcomes (partnership announcements…
Rising interest rates negatively impact Akebia through multiple channels: (1) Higher discount rates compress the present value of future…
Watch on earnings: Quarterly collaboration revenue from Mitsubishi Tanabe and any milestone payment announcements, Cash and cash equivalents balance relative to quarterly operating cash burn rate, Vafseo prescription volume trends in Japan from third-party data sources (IQVIA, Symphony Health).
One Sentence Summary:
Akebia Therapeutics: the story is balanced — vafseo commercial performance updates in japan - prescription trends, market share gains against competitors like evrenzo (roxadustat).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
